Exalenz finds positive news in Phase III study

Shares rose 13% as a secondary goal in the study was met successfully.

Exalenz Bioscience Ltd. (TASE:EXEN) today announced the final results of the Phase III clinical trial of its BreathID diagnostic kit for detecting severe liver damage.

The share rose 13.4% in morning trading to NIS 1.42, giving a market cap of NIS 115 million, after the company announced success in the secondary endpoint of the trial, although it reported two weeks ago that it had missed the primary endpoint.

The study found a strong (0.8) correlation between the Hepatic Impairment Score (HIS), developed by the company for assessing the probability of severe liver damage caused by Cirrhosis, and the risk of liver damage as measured by biopsy. This correlation was the secondary endpoint of the trial.

Exalenz CEO Steven Eitan said, "On the basis of the final results and conclusions obtained, we applied to the US Food and Drug Administration (FDA) to set a meeting for premarket approval (PMA) in order to apply for final approval to market the BreathID device in the US as a tool for assessing the probability of liver damage during 2010."

Last month, Exalenz announced that the trial of BreathID failed to achieve its primary endpoint: diagnosing severe liver damage, compared with the accuracy of biopsies of liver tissue.

The BreathID analyzes the patient's breath after digestion in order to diagnosis certain diseases.

Published by Globes [online], Israel business news - www.globes-online.com - on January 6, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017